middle.news
How INOVIQ’s $10.2M Raise Fuels Next-Gen Cancer Diagnostics and Therapies
8:56am on Wednesday 18th of February, 2026 AEDT
•
Healthcare
Read Story
How INOVIQ’s $10.2M Raise Fuels Next-Gen Cancer Diagnostics and Therapies
8:56am on Wednesday 18th of February, 2026 AEDT
Key Points
Net loss widened to $3.96 million for half-year ended 31 December 2025
Completed $10.2 million capital raise including $5 million cornerstone investment
EXO-NET customer base expanded across US, Europe and Asia
Exclusive licence secured for ovarian cancer biomarker from University of Queensland
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
INOVIQ (ASX:IIQ)
OPEN ARTICLE